Literature DB >> 23021430

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Keiji Oishi1, Yuka Mimura-Kimura, Taku Miyasho, Keisuke Aoe, Yoshiko Ogata, Hideki Katayama, Yoriyuki Murata, Hiroshi Ueoka, Tsuneo Matsumoto, Yusuke Mimura.   

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is characterized by severe worsening dyspnea of unknown etiology and high mortality without effective treatment. Recently, direct hemoperfusion with polymyxin B (PMX)-immobilized fiber cartridge (PMX-DHP) has been reported to improve pulmonary oxygenation and survival in patients with AE-IPF although its mechanism of action remains unknown. To gain insights into the pathobiology of AE-IPF through the beneficial effects of PMX-DHP, we analyzed the profile of cytokines adsorbed onto PMX-fibers used in 9 AE-IPF patients. In addition, the sera of these AE-IPF patients collected immediately before and after PMX-DHP, 9 stable IPF patients and 8 healthy individuals were also analyzed. The serum levels of cytokines including IL-9, IL-12, IL-17, PDGF and VEGF were significantly decreased immediately after PMX-DHP (P<0.02), and VEGF and IL-12 were most prominently reduced. In addition to PDGF and VEGF, IL-1β, IL-1ra, IL-8, IL-23, FGF basic, GM-CSF, IP-10, RANTES and TGF-β were eluted from used PMX-fibers. Interestingly, improved pulmonary oxygenation after PMX-DHP was correlated well with the quantities of eluted VEGF. These results suggest that adsorption of proinflammatory, profibrotic and proangiogenic cytokines onto PMX-fibers is one of the mechanisms of action of PMX-DHP in AE-IPF. Notably, removal of VEGF by PMX-DHP may contribute to the rapid improvement in oxygenation by suppressing vascular permeability in the lung.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021430     DOI: 10.1016/j.cyto.2012.08.032

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  26 in total

1.  Pharmacological treatment of acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study of 88 patients.

Authors:  Susumu Sakamoto; Hiroshige Shimizu; Takuma Isshiki; Atsuko Kurosaki; Sakae Homma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Authors:  Kerri Johannson; Harold R Collard
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 3.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 4.  Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review.

Authors:  Norio Kubo; Kenichiro Araki; Takahiro Yamanaka; Kouki Hoshino; Norihiro Ishii; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Keitaro Hirai; Fumiyoshi Saitoh; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Today       Date:  2017-03-01       Impact factor: 2.549

5.  Changes in Oxygenation and Serological Markers in Acute Exacerbation of Interstitial Lung Disease Treated with Polymyxin B Hemoperfusion.

Authors:  Song-I Lee; Chaeuk Chung; Dongil Park; Da Hyun Kang; Jeong Eun Lee
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

6.  Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.

Authors:  Tejaswini Kulkarni; Steven R Duncan
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

7.  The effects of direct hemoperfusion with polymyxin B-immobilized fiber in patients with acute exacerbation of interstitial lung disease.

Authors:  Jae Ha Lee; Jin Han Park; Hyo-Jung Kim; Hyun Kuk Kim; Ji Hoon Jang; Yong Kyun Kim; Bong Soo Park; Si Hyung Park; Il Hwan Kim; Se Hun Kim; Woon Heo; Hang-Jea Jang
Journal:  Acute Crit Care       Date:  2021-04-15

8.  Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival.

Authors:  Noriyuki Enomoto; Masashi Mikamo; Yoshiyuki Oyama; Masato Kono; Dai Hashimoto; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Hideo Yasuda; Akihiko Kato; Soichiro Mimuro; Matsuyuki Doi; Shigehito Sato; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2015-02-22       Impact factor: 3.317

9.  Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Hiromi Tomioka; Hirohito Takata
Journal:  Respirol Case Rep       Date:  2017-01-12

Review 10.  Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge.

Authors:  Elisabeth Esteban; Ricard Ferrer; Laia Alsina; Antonio Artigas
Journal:  Mediators Inflamm       Date:  2013-10-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.